Tomonori Ishii

16PUBLICATIONS
60CO-AUTHORS
Regenerative medicine (incl. stem cells)Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Immunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Aug 27, 2026
Rapid versus conventional glucocorticoid tapering in pure membranous LN: a multicentre retrospective study.

|Jun 26, 2026
Achievement of intermediate treatment targets for Still's disease under tocilizumab treatment: a post-hoc analysis of the phase III trial.

|Jan 29, 2026
Long-term safety and efficacy of tocilizumab in adult-onset Still's disease: open-label, long-term extension of the phase III trial.

Koji Suzuki, Hideto Kameda, Kei Ikeda

|Oct 25, 2025
Strong inhibition of IL-6 signal is clinically and serologically effective in refractory adult-onset Still's disease.

Koji Suzuki, Hideto Kameda, Kei Ikeda

|Jun 14, 2025
Serum cytokine levels towards precision medicine in Still's disease: a subanalysis of a randomized controlled trial of tocilizumab.

Koji Suzuki, Hideto Kameda, Kei Ikeda

|May 19, 2025
Protocol: Filgotinib in addition to methotrexate versus filgotinib monotherapy in patients with rheumatoid arthritis with an inadequate response to methotrexate: A multicenter, prospective, open-label, randomized controlled trial (FAITHFUL Study).

Mitsuhiro Akiyama, Toshihiko Hidaka, Motohide Kaneko

Pageof 3

Frequent Collaborators

7 joint publications

Hiroko Sato

6 joint publications

Hiroshi Fujii

6 joint publications

Yoshiya Tanaka

5 joint publications

Tsuyoshi Shirai